See more : Five Star Bancorp (FSBC) Income Statement Analysis – Financial Results
Complete financial analysis of Enzo Biochem, Inc. (ENZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Enzo Biochem, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- Octodec Investments Limited (OCT.JO) Income Statement Analysis – Financial Results
- PT Autopedia Sukses Lestari Tbk (ASLC.JK) Income Statement Analysis – Financial Results
- Toyo Drilube Co., Ltd. (4976.T) Income Statement Analysis – Financial Results
- Fragbite Group AB (publ) (FRAG.ST) Income Statement Analysis – Financial Results
- Tipco Asphalt Public Company Limited (TASCO-R.BK) Income Statement Analysis – Financial Results
Enzo Biochem, Inc. (ENZ)
About Enzo Biochem, Inc.
Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 30 patient service centers in New York and New Jersey; and a free-standing 'STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. It markets its products and services through its direct sales force and a network of distributors in the United States and internationally. The company was founded in 1976 and is headquartered in New York, New York.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 31.91M | 31.06M | 107.07M | 117.73M | 76.02M | 81.17M | 104.71M | 107.80M | 102.77M | 97.60M | 95.95M | 93.71M | 103.08M | 102.03M | 97.08M | 89.57M | 77.80M | 52.91M | 39.83M | 43.40M | 41.64M | 52.77M | 54.02M | 58.41M | 50.03M | 44.30M | 40.40M | 34.90M | 34.50M | 31.70M | 22.80M | 20.00M | 20.50M | 19.80M | 19.40M | 12.10M | 9.10M | 8.70M | 7.30M |
| Cost of Revenue | 17.28M | 19.50M | 65.10M | 64.15M | 52.25M | 57.92M | 60.39M | 59.48M | 57.19M | 54.77M | 54.27M | 54.84M | 55.97M | 53.82M | 52.12M | 53.06M | 40.22M | 23.23M | 16.09M | 14.74M | 13.10M | 11.78M | 10.85M | 17.42M | 14.10M | 14.30M | 13.80M | 13.80M | 13.60M | 12.10M | 9.30M | 6.70M | 6.20M | 21.20M | 5.20M | 3.60M | 1.90M | 1.70M | 1.40M |
| Gross Profit | 14.63M | 11.57M | 41.97M | 53.58M | 23.77M | 23.25M | 44.33M | 48.33M | 45.58M | 42.83M | 41.68M | 38.87M | 47.11M | 48.21M | 44.97M | 36.51M | 37.57M | 29.68M | 23.74M | 28.66M | 28.54M | 40.99M | 43.17M | 40.98M | 35.93M | 30.00M | 26.60M | 21.10M | 20.90M | 19.60M | 13.50M | 13.30M | 14.30M | -1.40M | 14.20M | 8.50M | 7.20M | 7.00M | 5.90M |
| Gross Profit Ratio | 45.86% | 37.24% | 39.20% | 45.51% | 31.27% | 28.64% | 42.33% | 44.83% | 44.35% | 43.88% | 43.44% | 41.48% | 45.70% | 47.25% | 46.32% | 40.76% | 48.30% | 56.09% | 59.60% | 66.03% | 68.53% | 77.67% | 79.92% | 70.17% | 71.81% | 67.72% | 65.84% | 60.46% | 60.58% | 61.83% | 59.21% | 66.50% | 69.76% | -7.07% | 73.20% | 70.25% | 79.12% | 80.46% | 80.82% |
| Research & Development | 2.64M | 3.90M | 3.77M | 3.25M | 4.45M | 3.18M | 3.21M | 2.93M | 3.52M | 3.35M | 3.14M | 3.89M | 6.29M | 7.81M | 9.70M | 9.22M | 8.64M | 9.39M | 7.90M | 8.45M | 8.08M | 8.31M | 6.18M | 6.08M | 5.43M | 4.40M | 4.00M | 3.60M | 3.10M | 2.40M | 1.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 24.36M | 27.20M | 53.71M | 44.91M | 49.69M | 44.27M | 44.47M | 44.01M | 43.59M | 41.07M | 41.80M | 43.65M | 51.65M | 48.90M | 52.09M | 45.51M | 43.72M | 41.25M | 35.99M | 30.51M | 32.69M | 28.30M | 28.00M | 25.67M | 23.49M | 20.40M | 19.90M | 16.00M | 17.50M | 17.10M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | -2.63M | 345.00K | 577.00K | 400.00K | 437.00K | 374.00K | 580.00K | 649.00K | 601.00K | 556.00K | 440.00K | 302.00K | 237.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 21.72M | 27.20M | 53.71M | 44.91M | 42.96M | 44.27M | 44.47M | 44.01M | 43.59M | 41.07M | 41.80M | 43.65M | 51.65M | 48.90M | 52.09M | 45.51M | 43.72M | 41.25M | 35.99M | 30.51M | 32.69M | 28.30M | 28.00M | 25.67M | 23.49M | 20.40M | 19.90M | 16.00M | 17.50M | 17.10M | 10.60M | 16.90M | 12.90M | 0.00 | 15.80M | 12.20M | 9.60M | 9.60M | 4.50M |
| Other Expenses | 0.00 | 380.00K | -1.19M | 6.91M | 488.00K | 382.00K | 168.00K | 125.00K | 122.00K | 95.00K | 194.00K | 5.00K | 5.10M | 4.43M | 3.48M | 5.84M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.93M | 1.90M | 1.90M | 1.80M | 1.80M | 1.80M | 1.50M | 1.50M | 700.00K | 1.20M | 500.00K | 300.00K | 0.00 | 500.00K | 300.00K |
| Operating Expenses | 27.00M | 31.11M | 57.47M | 48.16M | 47.41M | 47.44M | 51.37M | 49.71M | 49.45M | 46.70M | 48.01M | 52.04M | 63.05M | 61.14M | 65.28M | 60.57M | 52.36M | 50.64M | 43.89M | 38.96M | 40.77M | 36.61M | 34.18M | 31.75M | 30.84M | 26.70M | 25.80M | 21.40M | 22.40M | 21.30M | 13.90M | 18.40M | 13.60M | 1.20M | 16.30M | 12.50M | 10.10M | 10.10M | 4.80M |
| Cost & Expenses | 44.27M | 50.60M | 122.58M | 112.31M | 99.66M | 105.36M | 111.75M | 109.19M | 106.64M | 101.48M | 102.27M | 106.87M | 119.02M | 114.96M | 117.39M | 113.63M | 92.58M | 73.87M | 59.98M | 53.71M | 53.88M | 48.40M | 45.03M | 49.18M | 44.94M | 41.00M | 39.60M | 35.20M | 36.00M | 33.40M | 23.20M | 25.10M | 19.80M | 22.40M | 21.50M | 16.10M | 12.00M | 11.80M | 6.20M |
| Interest Income | 3.54M | 0.00 | 178.00K | 8.00K | 454.00K | 1.06M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 581.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 197.00K | 0.00 | 159.00K | 0.00 | 0.00 | 0.00 | 9.78M | 2.58M | 0.00 | 0.00 | 7.14M | 11.52M | 49.99M | 0.00 | 3.92M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 12.00M | 0.00 | 0.00 | 2.70M | 1.60M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.27M | 2.68M | 2.83M | 2.65M | 2.78M | 3.04M | 3.13M | 3.60M | 3.84M | 3.79M | 3.97M | 4.61M | 4.48M | 4.47M | 4.27M | 3.46M | 2.15M | 1.19M | 1.12M | 2.33M | 2.36M | 1.81M | 2.15M | 2.25M | 1.93M | 1.90M | 1.90M | 1.80M | 1.80M | 1.80M | 1.50M | 1.50M | 700.00K | 1.20M | 500.00K | 300.00K | 500.00K | 500.00K | 300.00K |
| EBITDA | -8.35M | -20.94M | -15.01M | 3.35M | -27.59M | -24.16M | -3.91M | 1.09M | -6.56M | -1.21M | -5.73M | -14.29M | -11.46M | -8.35M | -17.99M | -20.02M | -8.75M | -19.78M | -19.03M | -7.97M | -9.87M | 6.18M | 11.14M | 11.48M | 7.01M | 5.20M | 2.70M | 1.50M | 300.00K | 100.00K | 1.10M | -3.60M | 1.40M | -1.40M | -1.60M | -3.70M | -2.40M | -2.60M | 1.40M |
| EBITDA Ratio | -26.16% | -39.01% | -10.23% | 10.64% | -19.78% | 100.00% | 100.00% | 100.00% | 100.00% | -1.87% | 1.26% | -3.02% | 13.14% | -8.38% | -14.50% | -22.99% | -16.50% | -42.48% | -47.78% | -50.63% | -23.70% | 11.71% | 20.63% | 19.66% | 14.01% | 11.74% | 1.98% | -0.86% | 18.26% | -35.65% | -6.14% | -13.00% | 8.78% | 16.67% | -19.59% | -61.16% | -59.34% | -67.82% | -9.59% |
| Operating Income | -9.82M | -24.74M | -15.51M | 9.88M | -23.64M | 78.13M | -12.16M | -3.07M | 47.00M | -1.21M | -10.18M | -18.98M | -40.48M | -12.93M | -22.06M | -24.06M | -14.79M | -20.97M | -20.15M | -10.31M | -12.23M | 4.37M | 8.99M | 9.23M | 5.08M | 3.30M | 800.00K | -300.00K | -1.50M | -1.70M | -400.00K | -5.10M | 700.00K | -2.60M | -2.10M | -4.00M | -2.90M | -3.10M | 1.10M |
| Operating Income Ratio | -30.77% | -79.64% | -14.48% | 8.39% | -31.09% | 96.26% | -11.62% | -2.84% | 45.73% | -1.24% | -10.61% | -20.25% | -39.27% | -12.67% | -22.72% | -26.86% | -19.01% | -39.63% | -50.60% | -23.74% | -29.37% | 8.28% | 16.64% | 15.80% | 10.16% | 7.45% | 1.98% | -0.86% | -4.35% | -5.36% | -1.75% | -25.50% | 3.41% | -13.13% | -10.82% | -33.06% | -31.87% | -35.63% | 15.07% |
| Total Other Income/Expenses | 0.00 | -286.00K | -3.31M | 7.18M | 1.85M | 29.68M | 746.00K | 644.00K | 56.92M | -1.09M | 275.00K | 31.00K | -442.00K | 105.00K | -203.00K | -70.00K | 3.89M | 7.79M | 3.14M | 15.52M | 1.15M | 1.36M | 1.35M | 3.00M | 2.58M | 2.10M | 1.80M | 1.90M | -6.00M | 11.40M | 2.60M | -1.20M | -1.80M | 2.60M | -1.80M | 0.00 | 3.00M | -500.00K | 1.00M |
| Income Before Tax | -9.82M | -25.02M | -18.26M | 7.88M | -28.52M | 2.49M | -11.42M | -2.42M | 46.52M | -2.29M | -9.91M | -18.95M | -40.92M | -12.82M | -22.26M | -23.48M | -10.89M | -13.18M | -17.01M | 5.22M | -11.08M | 5.73M | 10.34M | 12.23M | 7.67M | 5.40M | 2.60M | 1.60M | -7.50M | 9.70M | 2.20M | -6.30M | -1.10M | -2.60M | -3.90M | -4.00M | 100.00K | -3.60M | 2.10M |
| Income Before Tax Ratio | -30.77% | -80.56% | -17.06% | 6.69% | -37.52% | 3.07% | -10.90% | -2.25% | 45.26% | -2.35% | -10.32% | -20.22% | -39.70% | -12.57% | -22.93% | -26.21% | -14.00% | -24.90% | -42.71% | 12.02% | -26.61% | 10.85% | 19.14% | 20.94% | 15.33% | 12.19% | 6.44% | 4.58% | -21.74% | 30.60% | 9.65% | -31.50% | -5.37% | -13.13% | -20.10% | -33.06% | 1.10% | -41.38% | 28.77% |
| Income Tax Expense | 0.00 | 12.30M | 4.32M | 4.45M | 5.37M | 101.27M | -1.10M | 82.00K | 1.23M | -7.00K | 72.00K | -712.00K | -1.65M | 137.00K | -28.00K | -87.00K | -239.00K | 85.00K | -1.34M | 2.21M | -4.85M | 1.88M | 3.42M | 5.42M | 1.04M | -1.10M | -800.00K | 100.00K | 200.00K | 4.10M | -2.90M | 100.00K | 100.00K | 12.90M | 200.00K | 100.00K | 600.00K | -2.00M | 600.00K |
| Net Income | -26.08M | 20.29M | -22.58M | 3.43M | -33.89M | -98.78M | -10.32M | -2.50M | 45.29M | -2.29M | -9.98M | -18.24M | -39.27M | -12.96M | -22.23M | -23.56M | -10.65M | -13.26M | -15.67M | 3.00M | -6.23M | 3.84M | 6.92M | 6.81M | 6.62M | 6.50M | 3.40M | 1.50M | -7.70M | 5.60M | 5.30M | -6.90M | -600.00K | -10.80M | -4.10M | -4.10M | -3.50M | -1.60M | 1.50M |
| Net Income Ratio | -81.73% | 65.32% | -21.09% | 2.91% | -44.58% | -121.70% | -9.86% | -2.32% | 44.06% | -2.34% | -10.40% | -19.46% | -38.09% | -12.70% | -22.90% | -26.31% | -13.69% | -25.06% | -39.34% | 6.92% | -14.96% | 7.28% | 12.82% | 11.66% | 13.24% | 14.67% | 8.42% | 4.30% | -22.32% | 17.67% | 23.25% | -34.50% | -2.93% | -54.55% | -21.13% | -33.88% | -38.46% | -18.39% | 20.55% |
| EPS | -0.51 | -1.27 | -0.46 | 0.07 | -0.71 | -2.09 | -0.22 | -0.05 | 0.98 | -0.05 | -0.23 | -0.46 | -1.01 | -0.34 | -0.59 | -0.63 | -0.29 | -0.38 | -0.49 | 0.09 | -0.20 | 0.11 | 0.22 | 0.22 | 0.22 | 0.21 | 0.12 | 0.05 | -0.27 | 0.19 | 0.19 | -0.29 | -0.03 | -0.71 | -0.26 | -0.27 | -0.24 | -0.11 | 0.09 |
| EPS Diluted | -0.51 | -1.27 | -0.46 | 0.07 | -0.71 | -2.08 | -0.22 | -0.05 | 0.97 | -0.05 | -0.23 | -0.46 | -1.01 | -0.34 | -0.59 | -0.63 | -0.29 | -0.38 | -0.49 | 0.09 | -0.20 | 0.11 | 0.22 | 0.21 | 0.20 | 0.21 | 0.11 | 0.05 | -0.27 | 0.19 | 0.18 | -0.29 | -0.03 | -0.71 | -0.26 | -0.27 | -0.24 | -0.11 | 0.09 |
| Weighted Avg Shares Out | 50.90M | 49.16M | 48.59M | 48.19M | 47.70M | 47.35M | 46.91M | 46.35M | 46.15M | 45.36M | 42.56M | 39.61M | 38.80M | 38.36M | 38.00M | 37.51M | 36.88M | 35.02M | 32.22M | 32.10M | 31.70M | 32.97M | 31.36M | 31.25M | 30.79M | 30.31M | 29.97M | 29.47M | 28.84M | 29.38M | 28.05M | 24.00M | 18.26M | 15.29M | 15.60M | 15.13M | 14.69M | 14.98M | 16.60M |
| Weighted Avg Shares Out (Dil) | 50.90M | 49.16M | 48.59M | 48.33M | 47.70M | 47.48M | 46.97M | 46.35M | 46.60M | 45.36M | 42.56M | 39.61M | 38.80M | 38.36M | 38.00M | 37.51M | 36.88M | 35.02M | 32.22M | 32.76M | 31.70M | 33.78M | 32.33M | 32.56M | 32.80M | 30.97M | 31.29M | 29.47M | 28.91M | 29.38M | 29.33M | 24.00M | 18.26M | 15.29M | 15.60M | 15.13M | 14.69M | 14.98M | 16.60M |
ENZ Stock Up Following FY24 Earnings Uptick, Gross Margin Expands
Enzo Biochem's overall topline benefits from revenue growth in the majority of its geographic regions.
Enzo Biochem Reports Fourth Quarter and Fiscal Year 2024 Results and Announces Cash Dividend
FARMINGDALE, N.Y., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the fiscal fourth quarter ended July 31, 2024 and the fiscal year ended July 31, 2024. The Company...
Enzo Biochem to pay $4.5 mln for failing to safeguard patient data
Enzo Biochem will pay $4.5 million to settle claims it failed to adequately safeguard personal and private health information of its patients, New York Attorney General Letitia James said on Tuedsay.
Enzo Biochem: Is This Time Finally Different?
Enzo Biochem shareholders frustrated with lack of capital returns following Clinical Labs sale to Labcorp Holdings. Stock trading near historic lows, but potential for attractive returns with simplified Life Sciences division and strong CEO incentives. Valuation potential of $2.00-3.22/share with...
Zacks Initiates Coverage of Enzo Biochem With Neutral Recommendation
Discover why Zacks rates Enzo Biochem as "Neutral", being the first on Wall Street to initiate coverage on the stock. Explore ENZ's notable revenue growth and financial health amid market challenges.
Enzo Biochem (ENZ) Q3 Earnings Improve Y/Y, Gross Margin Up
Enzo Biochem's (ENZ) overall topline benefits from revenue growth in the majority of its geographic regions.
Enzo Biochem Reports Third Quarter Fiscal 2024 Results and Provides Business Update
FARMINGDALE, N.Y., June 13, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the fiscal third quarter ended April 30, 2024.
Enzo Biochem Reports Second Quarter Fiscal 2024 Results and Provides Business Update
FARMINGDALE, N.Y., March 13, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the second quarter ended January 31, 2024.
Enzo Biochem Reports Results of its Annual Meeting of Shareholders and Officer Appointments
FARMINGDALE, NY, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading life science company, announced the voting results from its Annual Meeting held on January 31, 2024 and officer appointments.
ENZO BIOCHEM REPORTS FIRST QUARTER FISCAL 2024 RESULTS AND PROVIDES BUSINESS UPDATE
FARMINGDALE, NY, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the first quarter ended October 31, 2023.
Source: https://incomestatements.info
Category: Stock Reports